Platelets, plasma, and red blood cells
Since its inception in 1991, Concord, California's Cerus Corporation (NASDAQ:CERS) has focused nearly all of its resources into the development of the Intercept Blood System. Donated blood undergoes intense screening for every conceivable pathogen before separated into red blood cells [RBCs], plasma, platelets, and numerous other products. The Intercept Blood System is intended to stop the proliferation of any pathogens that pass the screening process, or find their way into blood products during the manufacturing process.
Stops all gene expression, just add light
Cerus's Intercept Plasma and Platelet Systems are based on amotosalen HCL, a synthetic version of naturally occurring compounds that insert themselves into DNA. When exposed to ultraviolet radiation amotosalen...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|